Kleo Pharmaceuticals ^Company

Kleo Pharmaceuticals and Green Cross LabCell (GCLC) are working in a COVID-19-targeting allogeneic Natural Killer (NK) cell combination therapy. It is a combination of Kleo’s first non-oncology application of its Antibody Recruiting Molecule (ARM ™) and GCLC’s NK cells. Kleo on March 31 said it had entered a research collaboration with GCLC to rapidly develop a COVID-19-targeting allogeneic NK cell combination therapy, combining Kleo's next-gen fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics with GCLC's allogeneic, or "off-the-shelf" NK cell therapies.